Trials / Terminated
TerminatedNCT00871741
Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 3, 5 and 11 Months of Age.
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 8 Weeks – 16 Weeks
- Healthy volunteers
- Accepted
Summary
This study will evaluate the safety and immunogenicity of GSK Biologicals' GSK2202083A vaccine given as a three-dose vaccination course at 3, 5 and 11 months of age.
Conditions
- Tetanus
- Poliomyelitis
- Neisseria Meningitidis
- Haemophilus Influenzae Type b
- Diphtheria
- Acellular Pertussis
- Hepatitis B
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | GSK2202083A vaccine | Intramuscular, three doses |
| BIOLOGICAL | Infanrix hexa | Intramuscular, three doses |
| BIOLOGICAL | Menjugate | Intramuscular, two doses |
Timeline
- Start date
- 2009-04-01
- Primary completion
- 2009-06-25
- Completion
- 2009-06-25
- First posted
- 2009-03-30
- Last updated
- 2018-06-06
- Results posted
- 2017-04-04
Locations
8 sites across 1 country: Slovakia
Source: ClinicalTrials.gov record NCT00871741. Inclusion in this directory is not an endorsement.